|
|
April 2001 Subscribe | Archived Issues |
|
Trastuzumab (Herceptin) Boosts Chemotherapy A study just published in the New England Journal of Medicine has found that the HER2 monoclonal antibody called trastuzumab-more commonly known as Herceptin-may improve the effectiveness of chemotherapy for certain women with metastatic breast cancer.
Specifically, a team of California researchers found that trastuzumab appeared to make chemotherapy more effective in women whose breast cancer exhibits an overabundance ("overexpression") of a protein called HER2-which occurs in up to a third of all breast cancers.
Complementary Approaches Acupuncture to Alleviate Nausea
|
Other Features Research Into Pain Management Lacking Increasing Participation in Research Trials Making Breast Surgery More Effective Using MRI and Ultrasound to Detect Breast Cancer FDA Cautious About Digital Mammograms Sticking with Mammograms...For Now Understanding - and Overcoming - Neutropenia Breast Reduction Surgery and Breast Cancer Risk Tracking Environmental Chemicals Chemokines May Hold Key to Breast Cancer Spread Reducing Weight to Reduce Risk
|
|
Quality Corner |